Hz. Ke et al., Lasofoxifene (CP-336,156) protects against the age-related changes in bonemass, bone strength, and total serum cholesterol in intact aged male rats, J BONE MIN, 16(4), 2001, pp. 765-773
The purpose of this study was to evaluate if long-term (6 months) treatment
with lasofoxifene (LAS), a new selective estrogen receptor modulator (SERM
), can protect against age-related changes in bone mass and bone strength i
n intact aged male rats. Sprague-Dawley male rats at 15 months of age were
treated (daily oral gavage) with either vehicle (n = 12) or LAS at 0.01 mg/
kg per day (n = 12) or 0.1 mg/kg per day (n = 11) for 6 months. A group of
15 rats was necropsied at 15 months of age and served as basal controls. No
significant change was found in body weight between basal and vehicle cont
rols. However, an age-related increase in fat body mass (+42%) and decrease
in lean body mass (-8.5 %) was observed in controls. Compared with vehicle
controls, LAS at both doses significantly decreased body weight and fat bo
dy mass but did not affect lean body mass. No significant difference was fo
und in prostate wet weight among all groups. Total serum cholesterol was si
gnificantly decreased in all LAS-treated rats compared with both the basal
and the vehicle controls. Both doses of LAS treatment completely prevented
the age-related increase in serum osteocalcin. Peripheral quantitative comp
uterized tomography (pQCT) analysis at the distal femoral metaphysis indica
ted that the age-related decrease in total density, trabecular density, and
cortical thickness was completely prevented by treatment,vith LAS at 0.01
mg/kg per day or 0.1 mg/kg per day. Histomorphometric analysis of proximal
tibial cancellous bone showed an age-related decrease in trabecular bone vo
lume (TBV; -46%), trabecular number (Tb.N), wall thickness (W.Th), mineral
apposition rate, and bone formation rate-tissue area referent. Moreover, an
age-related increase in trabecular separation (Tb.Sp) and eroded surface w
as observed. LAS at 0.01 mg/kg per day or 0.1 mg/kg per day completely prev
ented these age-related changes in bone mass, bone structure, and bone turn
over. Similarly, the age-related decrease in TBV and trabecular thickness (
Tb.Th) and the age-related increase in osteoclast number (Oc.N) and osteocl
ast surface (Oc.S) in the third lumbar vertebral cancellous bone were compl
etely prevented by treatment with LAS at both doses. Further, LAS at both d
oses completely prevented the age-related decrease in ultimate strength (-4
7%) and stiffness (-37%) of the fifth lumbar vertebral body. These results
show that treatment with LAS for 6 months in male rats completely prevents
the age-related decreases in bone mass and bone strength by inhibiting the
increased bone resorption and bone turnover associated with aging. Further,
LAS reduced total serum cholesterol and did not affect the prostate weight
in these rats. Our data support the potential use of a SERM for protecting
against the age-related changes in bone and serum cholesterol in elderly m
en.